MENU
+Compare
LRMR
Stock ticker: NASDAQ
AS OF
Nov 20, 04:58 PM (EDT)
Price
$3.37
Change
-$0.10 (-2.88%)
Capitalization
295.71M

LRMR Larimar Therapeutics Forecast, Technical & Fundamental Analysis

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform... Show more

LRMR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for LRMR with price predictions
Nov 19, 2025

LRMR in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2025

LRMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where LRMR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LRMR's RSI Oscillator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where LRMR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 19, 2025. You may want to consider a long position or call options on LRMR as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

LRMR moved below its 50-day moving average on October 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LRMR crossed bearishly below the 50-day moving average on October 31, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LRMR entered a downward trend on November 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.127) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.190).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LRMR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LRMR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

LRMR is expected to report earnings to fall 18.18% to -49 cents per share on March 18

Larimar Therapeutics LRMR Stock Earnings Reports
Q4'25
Est.
$-0.50
Q3'25
Missed
by $0.20
Q2'25
Beat
by $0.07
Q1'25
Missed
by $0.11
Q4'24
Missed
by $0.14
The last earnings report on November 05 showed earnings per share of -61 cents, missing the estimate of -41 cents. With 743.08K shares outstanding, the current market capitalization sits at 295.71M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which engages in the research and development of a therapeutic treatment for mitochondrial disorders and Friedreich's ataxia

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Three Bala Plaza East
Phone
+1 844 511-9056
Employees
42
Web
https://www.larimartx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SALRY13.930.03
+0.22%
Salmar ASA
BNPQY38.720.07
+0.17%
BNP Paribas
CSBB49.00N/A
N/A
CSB Bancorp, Inc.
PYNKF0.12N/A
N/A
Perimeter Medical Imaging AI, Inc.
LYPHF0.39N/A
N/A
Luye Pharma Group LTD.

LRMR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with OCUL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+1.92%
OCUL - LRMR
43%
Loosely correlated
+2.81%
MLTX - LRMR
43%
Loosely correlated
+1.12%
AMLX - LRMR
42%
Loosely correlated
+2.80%
ERAS - LRMR
42%
Loosely correlated
-3.32%
EYPT - LRMR
42%
Loosely correlated
+2.29%
More